Cantor Fitzgerald maintains Sarepta stock rating on revised estimates By Investing.com

Sarepta shares trade at $16.66, down 84% over the past year. Cantor Fitzgerald kept a Neutral rating and $21 12-month target but lowered 2026 revenue estimates to align with FactSet consensus while leaving its price target unchanged. Mizuho raised its target to $31 (Outperform), Jefferies reiterated Buy with a $30 target, and Freedom Capital lifted its target to $25, reflecting mixed analyst views. Sarepta initiated a new ENDEAVOR safety phase for ELEVIDYS in ~25 non-ambulatory DMD patients testing sirolimus to mitigate acute liver injury, with potential FDA discussions cited for March 2026 and signs of a possible recovery in H2 2026.

Analysis

The market is pricing this equity more like a binary regulatory/story bet than a steady-growth healthcare name; that compresses multiples and amplifies downside to any near-term safety headline while making upside highly non-linear. If sentiment shifts back to neutral on safety and key commercial channels (payers, major treaters) incrementally resume prescribing, a 2x re-rating from current depressed multiples is plausible within 6–12 months because the fixed-cost nature of gene therapy manufacturing means marginal revenue largely drops to the bottom line once utilization resumes.

A second-order winner from a sustained pullback in demand is the AAV/viral-vector supply chain: CMOs and single-use suppliers will face excess capacity that should pressure contract pricing and accelerate consolidation or margin compression for those vendors. That dynamic lowers future commercialization costs for competing gene-therapy entrants and raises the bar for new launches (they can undercut on price or use freed capacity to shorten time-to-market).

Key tail risks are legal/regulatory (class actions or label restrictions) that can permanently impair commercial optionality, and payer de-listing decisions that can take 3–12 months to play out. The central reversal mechanism is reputational repair — credible third-party safety mitigation data plus broad KOL re-acceptance could restore prescribing cadence within one to two commercial cycles (3–9 months).

Contrarian read: downside is asymmetric but capped relative to upside if the safety narrative is demonstrably addressed; this makes long-dated, limited-risk payoff structures (calendar spreads, wide call spreads) attractive versus straight equity. For portfolio construction, treat this as an idiosyncratic binary with event-tied sizing rather than a pure growth allocation.

Key Decisions for Investors

• Buy a defined-risk call spread on SRPT: purchase a 9–12 month ATM call and sell a call ~40–60% above ATM (1:1) to finance premium. Rationale: captures multi-month re-rating if safety narrative improves; max loss = premium paid, upside = difference between strikes minus premium, target return 2–4x if uptake resumes.
• If exposed, hedge near-term headline risk with short-dated puts: buy 2–3 month downside protection (~10–25% OTM) sized to limit portfolio drawdown to an acceptable loss. Rationale: protects against an acute safety/regulatory shock that could halve market cap within days.
• Pair trade for idiosyncratic recovery: modest long SRPT (event-sized position) paired with a short position in a broad biotech basket or ETF to isolate idiosyncratic recovery vs sector moves. Timeframe 3–12 months; reduces beta and focuses P&L on the company-specific catalyst.
• Rotate a portion of short-term risk capital into APP or SMCI as lower-beta alternatives: shift proceeds from trimming SRPT into APP (opportunity in app-monetization cyclicality) or SMCI (secular server/AI demand), holding 3–9 months. Rationale: redeploys capital from a binary to more secular growth exposures with smoother return profiles.